Valuation: 4basebio PLC

Market Cap 81.58M 109M 95.23M 87.52M 155M 10.37B 157M 1.05B 408M 5.1B 409M 400M 17.57B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 81.88M 109M 95.58M 87.84M 155M 10.41B 158M 1.05B 410M 5.12B 410M 402M 17.63B EV / Sales 2026 *
29.2x
EV / Sales 2027 * 8.94x
Free-Float
38.72%
Yield 2026 *
-
Yield 2027 * -
Current month+0.96%
1 month-4.11%
3 months+8.47%
6 months-14.63%
Current year-14.63%
1 week 500
Extreme 500
550
1 month 500
Extreme 500
550
Current year 420
Extreme 420
630
1 year 420
Extreme 420
1,040
3 years 420
Extreme 420
1,820
5 years 390
Extreme 390
1,820
10 years 175
Extreme 175
1,820
Manager TitleAgeSince
Chief Executive Officer 33 2026-02-09
Chief Tech/Sci/R&D Officer - 2025-02-28
Chief Operating Officer - 2026-03-11
Director TitleAgeSince
Director/Board Member 70 2020-12-21
Director/Board Member 33 2024-08-07
Chairman 60 2025-07-07
Date Insider Type Main position Quantity % Market Cap.
05-20Buy

Chief Executive Officer

1,863 0.0120%
02-15Buy

Chief Executive Officer

2,650 0.0171%
02-10Buy

Director

3,000 0.0193%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-46.70%-8.70% 109M
+1.70%+7.41%+2.50%+8.22% 49.92B
+0.92%+3.93%+399.71%+605.33% 40.23B
+1.89%+8.32%+26.06%-6.35% 34.55B
+2.38%+6.35%+21.25%+64.58% 33.09B
+3.96%+10.67%+8.30%+40.44% 27.51B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+133.27% 15.92B
+0.32%+0.58%+14.00%+19.59% 13.86B
+3.30%+0.76%+90.23%+99.12% 13.52B
Average +1.96%+5.24%+65.42%+106.17% 24.58B
Weighted average by Cap. +2.07%+6.53%+90.14%+137.84%

Financials

2026 *2027 *
Net sales 2.8M 3.74M 3.27M 3M 5.31M 356M 5.39M 36.06M 14.02M 175M 14.03M 13.73M 603M 12M 16.02M 14.01M 12.87M 22.76M 1.53B 23.11M 155M 60.08M 750M 60.15M 58.86M 2.58B
Net income -17.1M -22.84M -19.96M -18.35M -32.43M -2.17B -32.93M -220M -85.62M -1.07B -85.71M -83.87M -3.68B -
Net Debt 300K 401K 350K 322K 569K 38.14M 578K 3.86M 1.5M 18.75M 1.5M 1.47M 64.61M 25.7M 34.32M 30M 27.57M 48.75M 3.27B 49.48M 331M 129M 1.61B 129M 126M 5.53B
Logo 4basebio PLC
4basebio PLC is a United Kingdom-based life biotechnology company. The Company is focused on the development of advanced therapy medicinal products (ATMPs) through its synthetic Deoxyribonucleic acid (DNA) products and non-viral, cell-targeting nucleic acid delivery platform. The Company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines. Its synthetic DNA is produced via an enzymatic, cell-free manufacturing process. It utilizes a technology for primer-free DNA amplification called TruePrime, which enables high-yield and quality DNA production. By combining two enzymes, Trueprime technology achieves isothermal multiple displacement DNA amplification in a continuous cell-free process with high fidelity. The Company offers application-specific synthetic DNA solutions across mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines and non-viral delivery.
Employees
140
Date Price Change Volume
26-07-03 GBX 525.00 0.00% 585
26-07-02 GBX 525.00 -4.55% 207
26-07-01 GBX 550.00 +5.77% 77
26-06-30 GBX 520.00 -0.95% 2,428
26-06-29 GBX 525.00 0.00% 137
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.250GBP
Average target price
16.00GBP
Spread / Average Target
+204.76%

Annual profits - Rate of surprise